Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CER-350
- Development stage
- Preclinical
- Lead developer
- ABIONYX Pharma
01
Overview
CER-350 is an investigational small-molecule drug developed by Cerenis Therapeutics as part of its HDL-targeted and immuno-oncology pipeline. Publicly available pipeline summaries list CER-350 alongside CER-320 as an immuno-oncology program, but do not disclose its specific molecular target, mechanism of action, structure, or lead indication. It is not approved for any indication, and no detailed clinical trial, pharmacology, or formulation data have been published, suggesting that CER-350 remains at a very early or preclinical stage of development or has not advanced sufficiently to be broadly characterized in the literature.
Beyond the preview
Go deeper on CER-350.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CER-350.